Key result
S1PR3 activation with CYM-5541 attenuates pressure overload-induced cardiac remodeling, hypertrophy, and fibrosis.
Why the study?
The role of endothelial S1PR3 in pressure overload-induced cardiac remodeling and its contribution to fibrosis and inflammation was unclear.
Does endothelial S1PR3 modulation prevent or exacerbate pressure overload-induced cardiac remodeling in experimental models?
Does endothelial S1PR3 modulation prevent or exacerbate pressure overload-induced cardiac remodeling in experimental models?
This study identifies endothelial S1PR3 as a protective regulator against pressure overload-induced cardiac remodeling, suggesting it as a potential therapeutic target for heart failure.
S1PR3 activation attenuates remodeling in preclinical TAC models; leaves open therapeutic translation to human heart failure.
Endothelial dysfunction and inflammation are pivotal contributors to pathological cardiac remodeling and its progression toward heart failure (HF). Sphingosine-1-phosphate receptor 3 (S1PR3), a G protein-coupled receptor enriched in endothelial cells (ECs), is an important regulator of endothelial function, but its role in pressure overload-induced cardiac remodeling remains unclear. In this study, we observed a substantial reduction in S1PR3 levels in cardiac ECs following transverse aortic constriction (TAC). Endothelial-targeted S1PR3 knockdown aggravated TAC-induced cardiac remodeling, as evidenced by aggravated myocardial fibrosis, cardiac hypertrophy, microvascular rarefaction, and inflammatory cell infiltration. Mechanistically, both in vitro and in vivo analyses showed that S1PR3 deficiency promoted endothelial inflammatory activation and NF-κB-associated signaling, and altered endothelial paracrine communication with cardiac fibroblasts and cardiomyocytes, thereby contributing to fibroblast activation and cardiomyocyte hypertrophy under pathological stress. Conversely, endothelial S1PR3 overexpression alleviated TAC-induced cardiac remodeling. Importantly, pharmacological activation of S1PR3 with CYM-5541 also attenuated functional impairment, reduced fibrosis and hypertrophy, preserved myocardial microvascular density, and suppressed inflammatory responses after TAC. Collectively, our findings identify endothelial S1PR3 as a protective regulator in pressure overload-induced cardiac remodeling and support S1PR3 as a potential therapeutic target for limiting maladaptive cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied Pressure overload-induced cardiac remodeling. Endothelial S1PR3 knockdown, overexpression, or activation with CYM-5541 was evaluated on Cardiac remodeling, fibrosis, hypertrophy, microvascular rarefaction, and inflammatory cell infiltration. Pharmacological activation of S1PR3 with CYM-5541 attenuated functional impairment, reduced fibrosis and hypertrophy, and suppressed inflammatory responses in pressure overload-induced cardiac remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: